Prostate cancer

Handshake jigsaw puzzle
#AstraZeneca #Clinical trials #MSD #Prostate cancer #Scottish Medicines Consortium

Therapy for advanced prostate cancer approved in Scotland 

The Scottish Medicines Consortium (SMC) has accepted AstraZeneca and MSD’s Lynparza (olaparib) for use as combination therapy with abiraterone and prednisone or prednisolone for adult patients with metastatic castration resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated, regardless of biomarker status1. Prostate cancer is the most common… Read More

#Cancer Research #News #Regulatory

#Artificial intelligence (AI) #Cancer Research UK #Oncology #Prostate cancer #University of East Anglia #University of Oxford

AI reveals prostate cancer is not just one disease

Research published in Cell Genomics has shown that prostate cancer includes two different subtypes of the disease, also known as evotypes. This discovery was made by using artificial intelligence (AI) to help unlock new discoveries about the evolution of prostate cancer and could lead to the… Read More

#Cancer Research #News #Trending News

Prostate cancer cells
#Drug resistance #Oncology #Prostate cancer #The Institute of Cancer Research #The Institute of Oncology Research #The Royal Marsden NHS Foundation Trust

Researchers reverse prostate cancer drug resistance

Prostate cancer’s resistance to treatment can be reversed in some patients by stopping hijacked white blood cells from being ‘pulled into’ tumours, according to new research published in Nature. In an early clinical trial, researchers showed that blocking the messages cancer uses to hijack white blood… Read More

#Cancer Research #News #Trending News

Peptide
#Cancer research #HBC Immunology #Oncology #Peptides #Prostate cancer #Seed funding #Tumour microenvironment (TME)

Start-up to study peptides that modulate gene expression

HBC Immunology (a subsidiary of Hofseth BioCare) has secured seed capital financing of approximately $900,000 from external investors to commence preclinical animal trials with its patented peptides, FT-002 and FT-005. These are analogues of peptides discovered by HBC in ProGo bioactive peptides, which modulate iron metabolism… Read More

#News #Start-up Zone

Prostate cancer cells
#FDA #Gene mutation #Janssen #Oncology #Phase III trial #Prostate cancer

FDA approves dual action tablet for BRCA-positive prostate cancer

Janssen’s Akeega (niraparib and abiraterone acetate) is now available in the US for adult patients with deleterious or suspected deleterious BRCA-positive metastatic castration-resistant prostate cancer (mCRPC) following FDA approval. It is the first dual action tablet combining a PARP inhibitor with abiraterone acetate, given with prednisone, to be approved in… Read More

#News #Regulatory

Cancer research in laboratory
#Cancer research #Oncology #Phase II trial #Promontory Therapeutics #Prostate cancer

Promontory Therapeutics expands Phase II mCRPC trial

Promontory Therapeutics has treated its first patients in France as part of the ongoing Phase II clinical trial of PT-112 in patients with late-stage metastatic castration-resistant prostate cancer (mCRPC). The Phase II proof-of-concept study has the objective of characterising the benefit-risk ratio and selecting the optimal… Read More

#Cancer Research #News

Male patient with doctor
#AstraZeneca #FDA #Merck #Oncology #Phase III trial #Prostate cancer

FDA extends US approval for olaparib in prostate cancer

Lynparza (olaparib) has been approved in the US for the treatment of adult patients with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC). The PARP inhibitor, developed by AstraZeneca and Merck (MSD), is approved in combination with abiraterone and prednisone or prednisolone. This approval was based on… Read More

#News #Regulatory

European Commission
#Cancer research #European Commission #Janssen #Oncology #Phase III trial #Prostate cancer

EU approval for dual action prostate cancer therapy

The European Commission (EC) has granted marketing authorisation for Akeega (niraparib and abiraterone acetate [AA]) for adults with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic). The drug is given in the form of a dual action tablet (DAT), with prednisone or prednisolone, and is approved in… Read More

#News #Regulatory

Cancer research in laboratory
#AstraZeneca #Breast cancer #Cancer research #National Institute for Health and Care Excellence (NICE) #Oncology #Prostate cancer #The Institute of Cancer Research #UK

NICE approves olaparib for early-stage breast cancer and prostate cancer

The UK’s National Institute for Health and Clinical Excellence (NICE) has recommended that Lynparza (olaparib) can be used for NHS patients with both early-stage breast cancer and prostate cancer. Olaparib is PARP inhibitor that targets cancers linked to faulty BRCA1 or BRCA2 genes and works across many different cancer types. The… Read More

#News #Regulatory #Trending News

#Breast cancer #Cancer research #CAR-T #Drug discovery #Immunotherapy #Oncology #Pancreatic cancer #Prostate cancer #Solid tumours

Latest episode of the DDW Highlights podcast

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have seen a number of developments in the treatment of solid tumours… Read More

#News

#Breast cancer #Cancer research #CAR-T #Drug discovery #Immunotherapy #Oncology #Pancreatic cancer #Prostate cancer #Solid tumours

This week in drug discovery (20-24 March)

News round-up for 20-24 March by DDW Digital Content Editor Diana Spencer.  This week we have seen a number of developments in the treatment of solid tumours hitting the headlines. Pennsylvania researchers may have found a way to boost CAR-T therapy in these tumours, previously only successful in… Read More

#News

Doctor showing a model of the prostate
#Cancer research #Oncology #Phase III trial #Prostate cancer

Positive Phase III results for prostate cancer drug

Pfizer and Astellas have announced positive top-line results from the Phase III EMBARK trial evaluating XTANDI (enzalutamide) in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC) with high-risk biochemical recurrence (BCR). Patients enrolled in the trial were randomised to one of three study arms: XTANDI plus leuprolide,… Read More

#Cancer Research #News

Male patient with doctor
#Cancer research #CHMP #European Medicines Agency #Gene mutation #Oncology #Phase III trial #Prostate cancer

Prostate cancer combination therapy reduces risk of death

The combination therapy of niraparib and abiraterone acetate (AA) could become the first dual action tablet (DAT) available in the European Union for metastatic castration-resistant prostate cancer (mCRPC) with BRCA1/2 mutations.  Janssen’s Akeega has been recommended for marketing authorisation when given with prednisone (P) or prednisolone by the Committee for… Read More

#News #Regulatory

Prostate cancer cells
#Cancer research #Genetics / genomics #Janssen #Oncology #Phase III trial #Prostate cancer

PARP inhibitor slows progression in HRR-positive prostate cancer

Janssen has revealed updated results from the Phase III MAGNITUDE study, which show that a combination therapy including niraparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, slowed prostate cancer progression.  The drug was investigated in combination with abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate… Read More

#Cancer Research #News

Prostate-specific membrane antigen
#Cancer research #Europe #Novartis #Oncology #Prostate cancer

New prostate cancer drug approved in Europe

A new drug based on the active ingredient Lutetium-177 PSMA-617 has been approved by the European Commission for the treatment of metastatic prostate cancer carrying the surface molecule PSMA (prostate specific membrane antigen).   The drug was developed under the leadership of the German Cancer Research Center (DKFZ)… Read More

#Cancer Research #News #Trending News

#Cancer research #Covid-19 #Depression #Drug development #Drug discovery #FDA #Gene therapy #Malaria #Neuroscience #Olfactory disorders #Prostate cancer

Podcast: Keep up-to-date on the latest industry news

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry news.  The industry has seen breakthroughs announced in malaria treatment, epilepsy and major… Read More

#News